Clinical trial
Open access
Aug 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial
A phase 2 clinical trial investigating neoadjuvant zanidatamab (HER2-targeting antibody) in patients with early-stage HER2-positive breast cancer found de-escalation to HER2-targeted therapy alone may be feasible.
V. Valero, P. Pohlmann, J. Mouabbi et al.
· Nature Communications · 0 citations